Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

NCT02399137 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT02399137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02399137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
August 31, 2018
Enrollment
88 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer